Table 2. Patient characteristics.
| Number (%) | |
|---|---|
| Total | 60 |
| Male/female | 14(23)/46(77) |
| Age (years) | |
| Mean/median | 53/53.5 |
| Range | 28–78 |
| Diagnosis | |
| Breast cancer | 32 (53) |
| Colorectal cancer | 16 (27) |
| Gynaecological cancer | 6 (10) |
| Lung | 2 (3) |
| Prostate | 1 (2) |
| Unknown primary | 3 (5) |
| Treatment | |
| Adjuvant | 30 (50) |
| Metastatic | 30 (50) |
| Smoking status | |
| Non-smoker | 31 (52) |
| Ex-smoker | 20 (33) |
| Smoker | 8 (13) |
| Not available | 1 (2) |
| Alcohol consumption | |
| Nil | 39 (65) |
| ⩽100 g/week | 13 (22) |
| >100 g/week | 5 (8) |
| Not available | 3 (5) |
| Chemotherapy regimen a | |
| AC±T | 14 (23) |
| CEF | 13 (22) |
| FOLFOX | 8 (13) |
| XELIRI | 3 (5) |
| Other | 16 (27) |
a
AC±T=Adriamycin and cyclophosphamide± → taxane; CEF=cyclophosphamide, epirubicin, 5-fluorouracil; FOLFOX=oxaliplatin, 5-fluorouracil and folinic acid; XELIRI=capecitabine (Xeloda) and irinotecan.